BR112022000155A2 - Composição inibidora da micromolécula pi4kiiia, seu método de preparação, e uso da mesma - Google Patents

Composição inibidora da micromolécula pi4kiiia, seu método de preparação, e uso da mesma

Info

Publication number
BR112022000155A2
BR112022000155A2 BR112022000155A BR112022000155A BR112022000155A2 BR 112022000155 A2 BR112022000155 A2 BR 112022000155A2 BR 112022000155 A BR112022000155 A BR 112022000155A BR 112022000155 A BR112022000155 A BR 112022000155A BR 112022000155 A2 BR112022000155 A2 BR 112022000155A2
Authority
BR
Brazil
Prior art keywords
micromolecule
preparation
pi4kiiia
inhibitory composition
pharmaceutical composition
Prior art date
Application number
BR112022000155A
Other languages
English (en)
Portuguese (pt)
Inventor
Changping Jiao
Feng Wang
Fude Huang
Shu Yang
Xiaojun Zhou
Original Assignee
Nuo Beta Pharmaceutical Tech Shanghai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nuo Beta Pharmaceutical Tech Shanghai Co Ltd filed Critical Nuo Beta Pharmaceutical Tech Shanghai Co Ltd
Publication of BR112022000155A2 publication Critical patent/BR112022000155A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/28Compounds containing heavy metals
    • A61K31/285Arsenic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/36Arsenic; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
BR112022000155A 2019-07-05 2020-07-06 Composição inibidora da micromolécula pi4kiiia, seu método de preparação, e uso da mesma BR112022000155A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2019094831 2019-07-05
PCT/CN2020/100377 WO2021004422A1 (zh) 2019-07-05 2020-07-06 小分子PI4KIIIα抑制剂组合物、其制备方法及用途

Publications (1)

Publication Number Publication Date
BR112022000155A2 true BR112022000155A2 (pt) 2022-04-12

Family

ID=74115038

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022000155A BR112022000155A2 (pt) 2019-07-05 2020-07-06 Composição inibidora da micromolécula pi4kiiia, seu método de preparação, e uso da mesma

Country Status (15)

Country Link
US (1) US20230115711A1 (https=)
EP (1) EP3995134A4 (https=)
JP (1) JP2022538505A (https=)
KR (1) KR20220071175A (https=)
CN (2) CN118105372A (https=)
AU (1) AU2020309681A1 (https=)
BR (1) BR112022000155A2 (https=)
CA (1) CA3149104A1 (https=)
CO (1) CO2022001218A2 (https=)
IL (1) IL289586A (https=)
MX (1) MX2022000287A (https=)
PE (1) PE20220942A1 (https=)
PH (1) PH12022550254A1 (https=)
TW (1) TW202126294A (https=)
WO (1) WO2021004422A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114685566A (zh) * 2020-12-31 2022-07-01 江苏挪贝肽医药科技有限公司 氧化苯砷晶型i、晶型ii和晶型iii及其制备方法
JP2024537837A (ja) * 2021-09-30 2024-10-16 ヌオ-ベータ・ファーマシューティカル・テクノロジー(シャンハイ)カンパニー・リミテッド ハロゲン化フェニルアルシンオキシド化合物およびその用途
CN116478954B (zh) * 2023-02-14 2025-06-10 中国农业大学 水稻基因OsPI4K及其在水稻抗稻瘟病中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002365110A1 (en) * 2001-07-10 2003-07-15 Massachusetts Institute Of Technology Small molecule microarrays
EP2316943B1 (en) * 2007-07-05 2013-06-19 Novartis AG DSRNA for treating viral infection
WO2016172952A1 (zh) * 2015-04-30 2016-11-03 江苏挪贝肽医药科技有限公司 PI4KIIIα蛋白及相关的膜蛋白复合体在治疗阿尔茨海默病中的应用
CN112437674A (zh) * 2018-04-11 2021-03-02 新墨西哥科技大学研究园公司 用于药物递送的脂质前药
BR112022019864A2 (pt) * 2020-03-31 2022-11-16 Nuo Beta Pharmaceutical Tech Shanghai Co Ltd Composto de oxofenilarsina deuterada e uso do mesmo
JP2024537837A (ja) * 2021-09-30 2024-10-16 ヌオ-ベータ・ファーマシューティカル・テクノロジー(シャンハイ)カンパニー・リミテッド ハロゲン化フェニルアルシンオキシド化合物およびその用途

Also Published As

Publication number Publication date
AU2020309681A1 (en) 2022-02-24
KR20220071175A (ko) 2022-05-31
CO2022001218A2 (es) 2022-05-20
IL289586A (en) 2022-03-01
WO2021004422A1 (zh) 2021-01-14
CA3149104A1 (en) 2021-01-14
JP2022538505A (ja) 2022-09-02
EP3995134A4 (en) 2023-07-12
MX2022000287A (es) 2022-06-16
US20230115711A1 (en) 2023-04-13
EP3995134A1 (en) 2022-05-11
CN118105372A (zh) 2024-05-31
CN114555056B (zh) 2024-01-05
TW202126294A (zh) 2021-07-16
PE20220942A1 (es) 2022-05-31
PH12022550254A1 (en) 2023-06-26
CN114555056A (zh) 2022-05-27

Similar Documents

Publication Publication Date Title
CO2026004076A2 (es) Compuestos macrocíclicos, método de preparación de estos y uso de estos
DOP2022000124A (es) Derivados de pirazolilo útiles como agentes anticancerígenos
ECSP22018571A (es) Degradadores bifuncionales de brd9 y sus métodos de uso
CL2020002698A1 (es) Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos
UY38221A (es) Inhibidores de proteínas ras con g12c mutantes
CL2020003257A1 (es) Compuestos antagonistas de pcsk9.
ECSP21038390A (es) Compuestos, composiciones farmacéuticas y métodos de preparación de compuestos y de su uso como inhibidores de la cinasa atr
CO2023013050A2 (es) Composiciones de psilocibina, métodos para prepararlas y métodos de uso de estas
CL2022001743A1 (es) Dosis de gamma-hidroxibutirato (ghb)
MX385265B (es) Derivados de 3-(((((2s-5r)-2-carbamoil-7-oxo-1,6-diazabiciclo [3.2.1]octan-6-il)oxi)sulfonil)oxi)-2,2-dimetilprop noato y compuestos relacionados como profarmacos oralmente administrados de inhibidores de beta-lactamasa para el tratamiento de infecciones bacterianas
MX2020007625A (es) Inhibidor mtor, composicion farmaceutica y su uso.
AR107871A1 (es) Combinaciones de inhibidores de lsd1 para su uso en el tratamiento de tumores sólidos
MX2019015431A (es) Compuesto cíclico tipo cumarina como inhibidor de mek y su uso.
ECSP056194A (es) Derivados de pirazolo-quinazolina, procedimiento para su preparacion y su uso como inhibidores de quinasa
BR112016008016B8 (pt) Compostos inibidores de kras g12c, composição farmacêutica compreendendo ditos compostos, métodos para regular a atividade e para preparar uma proteína mutante kras, hras ou nras g12c, método para inibir a proliferação de uma população de células e usos terapêuticos dos ditos compostos
BR112015027114A8 (pt) compostos inibidores seletivos de histona desacetilase, sua composição farmacêutica e seu uso
UY37742A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
BR112023019435A2 (pt) Inibidores de nek7
BR112022000155A2 (pt) Composição inibidora da micromolécula pi4kiiia, seu método de preparação, e uso da mesma
CL2020002199A1 (es) Compuesto de anillo de metillactama y uso farmacéutico del mismo.
CO2021010493A2 (es) Compuestos de halo-alilamina y uso de los mismos
BR112022012205A2 (pt) Compostos ativos para receptores nucleares
MX2022003504A (es) Inhibidor de irak y metodo de preparacion para el mismo y uso del mismo.
CL2021000129A1 (es) Apirasas solubilizadas, métodos y usos
AR115913A1 (es) Formas de dosificación oral biodisponibles, uso, métodos

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements